Microbot Medical has announced the Baptist Hospital of Miami, US, as the second site taking part in the human clinical trial of its Liberty robotic system.

The Liberty robotic system, which secured US Food and Drug Administration (FDA) clearance last month, is a single-use endovascular system which aims to increase procedure efficiency. It integrates advanced robotic systems with intuitive control mechanisms, offering surgeons improved dexterity and accuracy.

The Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, is the second site announced by Microbot. This follows an announcement last month that the medtech company had partnered with Brigham and Women's Hospital in Boston, Massachusetts, as its first site for the clinical trial.

In December 2023, Microbot completed a pre-clinical study of the Liberty system, where three interventional radiologists performed 96 robotic navigations. The study included a microscopic evaluation of target vessels and surrounding tissues after using various commercially available intravascular catheters controlled by Liberty. Endovascular surgery is a minimally invasive procedure that uses catheters to access blood vessels for the treatment of vascular diseases.

In June 2023, Microbot secured NIS1.62m ($440,000) in funding from the Israel Innovation Authority to further develop its manufacturing process for the Liberty system.

The surgical robotics space continues to make waves in the medtech sector. In February 2024, Virtual Incision’s MIRA surgical robot system secured FDA clearance for adult colectomy procedures. Earlier that month, the system began its journey to the International Space Station (ISS) to test the limits of remote surgical robotics.

According to GlobalData, the surgical robotics market is projected to reach $10bn globally by the end of 2024, growing to $15.8bn by 2030. One of the reasons for this growth is increasing demand from the growing elderly population seeking less invasive and precise surgical options, according to GlobalData Medical Analyst Graysen Vigneux.

Microbot’s CEO Harel Gadot said: “We believe the interest in the Liberty technology is overwhelming, as evident by the fast pace of enrolling and activating leading sites into the pivotal trial since we announced the IDE. We are excited for our partnership with Baptist Hospital of Miami, which is one of the leading hospitals in the United States.”

"Microbot secures second site for Liberty endovascular robot trial" was originally created and published by Medical Device Network, a GlobalData owned brand.